[HTML][HTML] Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed …
NS Joseph, JL Kaufman, MV Dhodapkar… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2020•ncbi.nlm.nih.gov
PURPOSE The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a
highly effective and convenient induction regimen for both transplantation-eligible and-
ineligible patients with myeloma. Here, we present the largest cohort of patients
consecutively treated with RVD induction therapy followed by risk-adapted maintenance
therapy with the longest follow-up and important information on long-term outcomes.
highly effective and convenient induction regimen for both transplantation-eligible and-
ineligible patients with myeloma. Here, we present the largest cohort of patients
consecutively treated with RVD induction therapy followed by risk-adapted maintenance
therapy with the longest follow-up and important information on long-term outcomes.
Abstract
PURPOSE
The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and-ineligible patients with myeloma. Here, we present the largest cohort of patients consecutively treated with RVD induction therapy followed by risk-adapted maintenance therapy with the longest follow-up and important information on long-term outcomes.
ncbi.nlm.nih.gov